NO148108B - ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ISOQINOLINE ACETAMIDE DERIVATIVES - Google Patents
ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ISOQINOLINE ACETAMIDE DERIVATIVES Download PDFInfo
- Publication number
- NO148108B NO148108B NO774500A NO774500A NO148108B NO 148108 B NO148108 B NO 148108B NO 774500 A NO774500 A NO 774500A NO 774500 A NO774500 A NO 774500A NO 148108 B NO148108 B NO 148108B
- Authority
- NO
- Norway
- Prior art keywords
- benzyloxycarbonyl
- dimethoxy
- tetrahydro
- isoquinoline
- general formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 15
- AYUXCIIIKHHZLA-UHFFFAOYSA-N 2-(6,7-dimethoxy-2-phenylmethoxycarbonyl-3,4-dihydro-1H-isoquinolin-1-yl)acetic acid Chemical compound C(C1=CC=CC=C1)OC(=O)N1C(C2=CC(=C(C=C2CC1)OC)OC)CC(=O)O AYUXCIIIKHHZLA-UHFFFAOYSA-N 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 10
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 10
- -1 benzyloxycarbonyl halide Chemical class 0.000 claims description 10
- UEXHGUMUCVTSNK-UHFFFAOYSA-N 2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-ium-1-yl)acetate Chemical compound C1CNC(CC(O)=O)C2=C1C=C(OC)C(OC)=C2 UEXHGUMUCVTSNK-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000000053 physical method Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 206010030124 Oedema peripheral Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229960002895 phenylbutazone Drugs 0.000 description 3
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 150000007860 aryl ester derivatives Chemical class 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- YOWAEZWWQFSEJD-UHFFFAOYSA-N quinoxalin-2-amine Chemical compound C1=CC=CC2=NC(N)=CN=C21 YOWAEZWWQFSEJD-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NUURWENDUMEZTR-UHFFFAOYSA-N 2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)-N-quinoxalin-2-ylacetamide Chemical compound N1=C(C=NC2=CC=CC=C12)NC(CC1NCCC2=CC(=C(C=C12)OC)OC)=O NUURWENDUMEZTR-UHFFFAOYSA-N 0.000 description 1
- MYURTHQBJNTYHX-UHFFFAOYSA-N 2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide Chemical class C1CNC(CC(N)=O)C2=C1C=C(OC)C(OC)=C2 MYURTHQBJNTYHX-UHFFFAOYSA-N 0.000 description 1
- BAXRJVHQHYXZKJ-UHFFFAOYSA-N COC1=C(C=C2C(N(C=CC2=C1)C(=O)OCC3=CC=CC=C3)CC(=O)Cl)OC Chemical compound COC1=C(C=C2C(N(C=CC2=C1)C(=O)OCC3=CC=CC=C3)CC(=O)Cl)OC BAXRJVHQHYXZKJ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- AGKQLTQKQZRGFX-UHFFFAOYSA-N benzyl 1-(2-amino-2-oxoethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylate Chemical class COC1=CC2=C(C=C1OC)C(CC(N)=O)N(CC2)C(=O)OCC1=CC=CC=C1 AGKQLTQKQZRGFX-UHFFFAOYSA-N 0.000 description 1
- JCMQLFHHQJMSOL-UHFFFAOYSA-N benzyl 1-(2-anilino-2-oxoethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylate Chemical compound C(C1=CC=CC=C1)OC(=O)N1C(C2=CC(=C(C=C2CC1)OC)OC)CC(=O)NC1=CC=CC=C1 JCMQLFHHQJMSOL-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Description
Foreliggende oppfinnelse angår en analogifremgangsmåte ved fremstilling av nye, terapeutisk aktive 6,7-dimethoxy-1,2,3,4-tetrahydro-l-isokinolin-derivater med den generelle formel: The present invention relates to an analogous method for the production of new, therapeutically active 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline derivatives with the general formula:
hvor where
R"*" er hydrogen eller benzyloxycarbonyl, og R"*" is hydrogen or benzyloxycarbonyl, and
R 2 er pyridyl, thiazolyl, kinoxalyl eller fenyl, hvor fenyl-gruppen eventuelt er substituert med C^_4~alkoxy, C2_^-alkanoyl, C1_^-alkyl og/eller med 1 eller 2 halogenatomer. R 2 is pyridyl, thiazolyl, quinoxalyl or phenyl, where the phenyl group is optionally substituted with C₁₄₄ alkoxy, C₂₄₄-alkanoyl, C₁₄₄-alkyl and/or with 1 or 2 halogen atoms.
De nye forbindelser med formel I kan fremstilles ved å omsette 6,7-dimethoxy-l,2,3,4-tetrahydro-l-isokinolin-eddiksyre med formelen: The new compounds of formula I can be prepared by reacting 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid with the formula:
med benzyloxycarbonylhalogenid og omsette den således dannede 2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetrahydro-l-isokinolin-eddiksyre med formelen: eller et reaktivt syrederivat med den generelle formel: with benzyloxycarbonyl halide and react the thus formed 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid with the formula: or a reactive acid derivative with the general formula:
derav, hvor hence, where
R 3 er C^_4~alkoxy eller fenoxy eventuelt substituert med nitro, R 3 is C₁₄₄₄ alkoxy or phenoxy optionally substituted with nitro,
med et amin med den generelle formel: with an amine of the general formula:
hvor R 2 er som ovenfor angitt, og eventuelt fjerne benzyloxy-carbonylgruppen, og eventuelt overføre den erholdte forbindelse med den generelle formel I til et farmasøytisk godtagbart salt derav eller å frigjøre den fra sitt salt. where R 2 is as indicated above, and optionally remove the benzyloxy-carbonyl group, and optionally transfer the obtained compound of the general formula I to a pharmaceutically acceptable salt thereof or to liberate it from its salt.
1-(2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetrahydro-isokinolyl)- og 6,7-dimethoxy-l,2,3,4-tetrahydro-l-isokinolin-acetamidene med den generelle formel I er nye forbindelser. N-alkyl- og N-aralkylacetamid-derivatene som strukturelt er mest lik forbindelsene ifølge oppfinnelsen, ble fremstilt avLombardino, J. G. et al. [J. Med. Chem. 3, 505 (1961), USP The 1-(2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolyl)- and 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline acetamides with the general formula I are new compounds. The N-alkyl and N-aralkylacetamide derivatives which are structurally most similar to the compounds of the invention were prepared by Lombardino, J.G. et al. [J. With. Chem. 3, 505 (1961), USP
nr. 3 021 331 C. A. 57, 786 d (1962)], og forbindelsene ble anvendt som utgangsmaterialer ved fremstilling av kondenserte cycliske forbindelser. No. 3,021,331 C. A. 57, 786 d (1962)], and the compounds were used as starting materials in the preparation of condensed cyclic compounds.
De ovennevnte forbindelser ble anvendt som utgangsmaterialer også ifølge US P nr. 3 654 281 C. A. 11_, 19688a (1972). Den biologiske aktivitet av forbindelsene med den generelle formel I som fremstilles ifølge oppfinnelsen, kunne ikke forut-sees på basis av de ovennevnte publikasjoner. The above-mentioned compounds were used as starting materials also according to US P No. 3,654,281 C. A. 11_, 19688a (1972). The biological activity of the compounds of the general formula I produced according to the invention could not be predicted on the basis of the above-mentioned publications.
Ved foreliggende fremgangsmåte omsettes 6,7-dimethoxy-1,2,3,4-tetrahydro-l-isokinolin-eddiksyre med den generelle formel IX med benzyloxycarbonylklorid. Reaksjonen utføres i et oppløsningsmiddel eller i fravær av et oppløsningsmiddel ved en reaksjonstemperatur på fra -10° til +100°C. I løpet av reaksjonen frigjøres saltsyre som bindes med en organisk eller uorganisk base. Som organiske baser kan fortrinnsvis tertiære aminer, som triethylamin, dimethylamin eller pyridin, anvendes, men et overskudd av isokinolinderivatene kan også anvendes som et syrebindende middel. Som uorganiske baser kan et alkali-hydroxyd, alkalicarbonat, jordalkalimetallhydroxyd eller In the present method, 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid of the general formula IX is reacted with benzyloxycarbonyl chloride. The reaction is carried out in a solvent or in the absence of a solvent at a reaction temperature of from -10° to +100°C. During the reaction, hydrochloric acid is released which binds with an organic or inorganic base. Tertiary amines, such as triethylamine, dimethylamine or pyridine, can preferably be used as organic bases, but an excess of the isoquinoline derivatives can also be used as an acid-binding agent. As inorganic bases, an alkali hydroxide, alkali carbonate, alkaline earth metal hydroxide or
-carbonat anvendes. Reaksjonen kan utføres i et oppløsnings-middel. Som oppløsningsmiddel kan vann, lavere alkylalkoholer, ketoner og ethere anvendes. Reaksjonen kan utføres ved å til-sette 6,7-dimethoxy-l,2,3,4-tetrahydro-l-isokinolin-eddiksyre -carbonate is used. The reaction can be carried out in a solvent. Water, lower alkyl alcohols, ketones and ethers can be used as solvents. The reaction can be carried out by adding 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid
til oppløsningen av den ekvimolare base, og benzyloxycarbonylklorid tildryppes under omrøring og avkjøling. Reaksjonen er fullstendig efter omrøring i 1 - 8 timer. Produktet isoleres efter surgjøring ved filtrering eller eventuelt ved inndampning. Det således erholdte faste stoff renses eventuelt ved krystallisasjon eller ved andre fysikalske metoder. to the solution of the equimolar base, and benzyloxycarbonyl chloride is added dropwise with stirring and cooling. The reaction is complete after stirring for 1 - 8 hours. The product is isolated after acidification by filtration or possibly by evaporation. The solid thus obtained is optionally purified by crystallization or by other physical methods.
Den erholdte 2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetrahydro-l-isokinolin-eddiksyre omsettes med et amin med den generelle formel: The 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid obtained is reacted with an amine of the general formula:
hvor R 2 er som ovenfor angitt, where R 2 is as indicated above,
i nærvær av et tertiært amin som triethylamin og alkoxycarbonyl-klorid som isobutyloxycarbonylklorid. Reaksjonen utføres eventuelt i et oppløsningsmiddel. Som oppløsningsmiddel kan fortrinnsvis anvendes ketoner, ethere som aceton, methylethyl-keton og tetrahydrofuran. Reaksjonen kan utføres ved en temperatur i området fra -15°Ctil +30°C. Temperaturen holdes fortrinnsvis under +5°C under reaksjonen og avsluttes ved 20 til 25°C. Produktet isoleres fortrinnsvis fra reaksjonsblandingen ved frafiltrering av det dannede tertiære aminsalt og inndampning av filtratet. Residuet inneholder det ønskede produkt som eventuelt renses ved en fysikalsk metode som krystallisasjon. in the presence of a tertiary amine such as triethylamine and alkoxycarbonyl chloride such as isobutyloxycarbonyl chloride. The reaction is optionally carried out in a solvent. Ketones, ethers such as acetone, methylethyl ketone and tetrahydrofuran can preferably be used as solvents. The reaction can be carried out at a temperature in the range from -15°C to +30°C. The temperature is preferably kept below +5°C during the reaction and ends at 20 to 25°C. The product is preferably isolated from the reaction mixture by filtering off the formed tertiary amine salt and evaporating the filtrate. The residue contains the desired product, which may be purified by a physical method such as crystallization.
I henhold til en videre utførelsesform av foreliggende fremgangsmåte omsettes en alkyl- eller arylester av 2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetrahydroisokinolin-l-eddiksyre med den generelle formel XI (fremstilt fra en syre eller et syreklorid med den generelle formel X, på i og for seg kjent vis) med et amin med den generelle formel V. Omsetningen kan utføres i et oppløsningsmiddel eller i fravær av et oppløsnings-middel ved å oppvarme reaktantene. Som oppløsningsmiddel kan aromatiske eller alifatiske hydrocarboner, alkoholer eller ethere anvendes. Alkoholen som dannes under reaksjonen, av-destilleres fortrinnsvis. Reaksjonen kan utføres ved å anvende såkalte aktive estere, som p-nitrofenylester. Reaksjonstempera-turen og reaksjonstiden avhenger av substituenten R 3, dvs. According to a further embodiment of the present method, an alkyl or aryl ester of 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-1-acetic acid is reacted with the general formula XI (prepared from an acid or an acid chloride of the general formula X, in a manner known per se) with an amine of the general formula V. The reaction can be carried out in a solvent or in the absence of a solvent by heating the reactants. Aromatic or aliphatic hydrocarbons, alcohols or ethers can be used as solvents. The alcohol formed during the reaction is preferably distilled off. The reaction can be carried out by using so-called active esters, such as p-nitrophenyl ester. The reaction temperature and reaction time depend on the substituent R 3, i.e.
typen av ester som anvendes ved reaksjonen. I tilfelle av alkylestere kreves en høyere temperatur (50 - 150°C) og en lengre reaksjonstid (2 - 10 timer) enn når arylestere, særlig aktive estere, anvendes. Efter at reaksjonen er avsluttet, c fjernes det faste stoff ved filtrering eller inndampning. Det faste stoff renses eventuelt ved fysikalske metoder som krystallisasjon. the type of ester used in the reaction. In the case of alkyl esters, a higher temperature (50 - 150°C) and a longer reaction time (2 - 10 hours) are required than when aryl esters, particularly active esters, are used. After the reaction has ended, c the solid is removed by filtration or evaporation. The solid substance is optionally purified by physical methods such as crystallization.
Ved et videre alternativ av fremgangsmåten ifølge oppfinnelsen omsettes 2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetrahydroisokinolin-l-eddiksyre med aminer med den gener- In a further alternative of the method according to the invention, 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-1-acetic acid is reacted with amines with the gene
elle formel V i nærvær av carbodiimider, som dicyclohexyl-carbodiimid. Reaksjonen utføres fortrinnsvis i et oppløsnings-middel. Som oppløsningsmiddel anvendes fortrinnsvis aromatiske eller alifatiske hydrocarboner som benzen og homologer derav, bensin, etc, ketoner som aceton, acetofenon, ethere som ethyl-ether, dioxan og tetrahydrofuran. Reaksjonen foregår lett, og den utføres derfor fortrinnsvis ved en lav temperatur som fra -20° til +30°C. I løpet av reaksjonen dannes et ureaderivat fra carbodiimidet som felles som et uoppløselig fast stoff. Efter at reaksjonen er fullstendig, frafiltreres det uoppløselige ureaderivat og filtratet inndampes for å utvinne produktet, som eventuelt renses ved krystallisasjon eller ved annen fysikalsk metode. or formula V in the presence of carbodiimides, such as dicyclohexylcarbodiimide. The reaction is preferably carried out in a solvent. Aromatic or aliphatic hydrocarbons such as benzene and homologues thereof, petrol, etc., ketones such as acetone, acetophenone, ethers such as ethyl ether, dioxane and tetrahydrofuran are preferably used as solvents. The reaction takes place easily, and it is therefore preferably carried out at a low temperature such as from -20° to +30°C. During the reaction, a urea derivative is formed from the carbodiimide which collects as an insoluble solid. After the reaction is complete, the insoluble urea derivative is filtered off and the filtrate is evaporated to recover the product, which is optionally purified by crystallization or by another physical method.
Ved et ytterligere alternativ av fremgangsmåten ifølge oppfinnelsen omsettes 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydroisokinolin-l-eddiksyre med den generelle formel X fortrinnsvis under oppvarmning med aminer med den generelle formel V. Reaksjonen kan utføres i nærvær eller i fravær av et oppløsningsmiddel. Som oppløsningsmiddel anvendes fortrinnsvis et oppløsningsmiddel som ikke er blandbart med vann, og vannet som dannes under reaksjonen, fjernes ved azeo-trop destillasjon. Likevekten skiftes således i retning av dannelse av syreamidene med formel I. Når der arbeides uten oppløsningsmiddel, oppvarmes syrene med den generelle formel X sammen med aminene med den generelle formel V ved 100 - 200°C. Fjernelse av det dannede vann er ønskelig også i dette tilfelle. Dette kan gjøres ved å utføre reaksjonen i et åpent kar, eller nitrogen eller en annen inert gass føres over reaksjonsblandingen. Reaksjonen kan utføres i vakuum. Når et oppløsningsmiddel anvendes, fjernes oppløsningsmidlet ved destillasjon efter at reaksjonen er fullstendig, og det således erholdte produkt renses eventuelt ved krystallisasjon. In a further alternative of the method according to the invention, 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-1-acetic acid of the general formula X is preferably reacted under heating with amines of the general formula V. The reaction can carried out in the presence or absence of a solvent. A solvent that is not miscible with water is preferably used as a solvent, and the water formed during the reaction is removed by azeotropic distillation. The equilibrium is thus shifted in the direction of formation of the acid amides with formula I. When working without a solvent, the acids with the general formula X are heated together with the amines with the general formula V at 100 - 200°C. Removal of the formed water is also desirable in this case. This can be done by carrying out the reaction in an open vessel, or nitrogen or another inert gas is passed over the reaction mixture. The reaction can be carried out in a vacuum. When a solvent is used, the solvent is removed by distillation after the reaction is complete, and the product thus obtained is optionally purified by crystallization.
Benzyloxy-carbonylgruppen fjernes så eventuelt fra de erholdte 2-benzyloxycarbonyl-6,7-dimethoxy-152 , 3 >4-t et rahydro-1-isokinolin-acet amdd-derivater ved å oppløse benzyloxycarbonyl-derivatet i konsentrert eddiksyre inneholdende hydrogenbromid, og efter henstand krystalliserer et 6,7-dimethoxy-1,2,3,4-tetrahydro-l-isokinolin-acetamid-derivat The benzyloxy-carbonyl group is then optionally removed from the obtained 2-benzyloxycarbonyl-6,7-dimethoxy-152 , 3>4-t rahydro-1-isoquinoline-acet amdd derivatives by dissolving the benzyloxycarbonyl derivative in concentrated acetic acid containing hydrogen bromide, and after standing, a 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetamide derivative crystallizes
fra oppløsningen og kan isoleres ved filtrering. from the solution and can be isolated by filtration.
Benzyloxycarbonylgruppen kan likeledes fjernes ved kata-lytisk hydrogenering. Benzyloxycarbonyl-derivatet oppløses i et oppløsningsmiddel og hydrogeneres i nærvær av en hydrogenover-føringskatalysator som palladium/trekull. Katalysatoren f rafil-treres, og produktet kan utvinnes ved filtrering eller inndampning. The benzyloxycarbonyl group can likewise be removed by catalytic hydrogenation. The benzyloxycarbonyl derivative is dissolved in a solvent and hydrogenated in the presence of a hydrogen transfer catalyst such as palladium/charcoal. The catalyst is filtered off, and the product can be recovered by filtration or evaporation.
Fremgangsmåteforbindelsene er effektive antiinflammatoriske midler. Denne antiinflammatoriske aktivitet er høyere enn den antiinflammatoriske aktivitet av det kjente fenylbutazon, og toksisiteten av forbindelsene er også lavere enn den for fenylbutazonet. Således bevirker N-(2-kinoxalyl)-6, 7-dimethoxy-1,2,3,4-tetrahydro-l-isokinolin-acetamid en inhiber- The process compounds are effective anti-inflammatory agents. This anti-inflammatory activity is higher than the anti-inflammatory activity of the known phenylbutazone, and the toxicity of the compounds is also lower than that of the phenylbutazone. Thus N-(2-quinoxalyl)-6, 7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetamide causes an inhibitory
ing på 44% i en carrageenin-fotødema-prøve i mus ved en 25 mg/kg i.p. dose, en inhibering på 30% ved en dose på 2,5 mg/kg i rotter og en inhibering på 47%, i en dose på 10 mg/kg i rotter. Ved administrasjon i.p. av en dose på 80 mg/kg inntrådte ingen død av mus . ing of 44% in a carrageenin foot edema test in mice at a 25 mg/kg i.p. dose, an inhibition of 30% at a dose of 2.5 mg/kg in rats and an inhibition of 47% at a dose of 10 mg/kg in rats. In case of administration i.p. of a dose of 80 mg/kg no death of mice occurred.
N-(p-methoxyfenyl)-6,7-dimethoxy-1,2,3,4~tetrahydro-1-isokinolin-acetamid bevirker en inhibering på 25% i en carrageenin-fotødema-prøve på rotter administrert i.p. i en dose på 10 mg/kg, og en inhibering på 57% i en dose på 25 mg/kg. Toksisiteten administrert til mus i.p. er 280 mg/kg. N-(p-methoxyphenyl)-6,7-dimethoxy-1,2,3,4~tetrahydro-1-isoquinoline-acetamide produces a 25% inhibition in a carrageenin photoedema test in rats administered i.p. in a dose of 10 mg/kg, and an inhibition of 57% in a dose of 25 mg/kg. The toxicity administered to mice i.p. is 280 mg/kg.
l-(p-klorbenzoyl) -2-methyl-5-methoxy-2-indolyl-eddiksyre,. det kjente indomethacin, bevirker en inhibering på 50% i carra-geenin-f ot ødema -prøven på rotter administrert i.p. i en dose på 10 mg/kg, og toksisiteten er 33 mg/kg administrert pr. os. 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-2-indolyl-acetic acid,. the known indomethacin, causes an inhibition of 50% in the carrageenin foot edema test in rats administered i.p. in a dose of 10 mg/kg, and the toxicity is 33 mg/kg administered per us.
Fenylbutazonet, (4-n-butyl-1,2-dif eny1-pyrazolidin-3,5-dion), bevirker en inhibering på 22% i en carrageenin-fotødema-prøve på rotter ved en dose på 30 mg/kg, og toksisiteten administrert p.o. til mus er 660 mg/kg. The phenylbutazone, (4-n-butyl-1,2-diphenyl-1-pyrazolidine-3,5-dione), produces a 22% inhibition in a carrageenin foot edema test in rats at a dose of 30 mg/kg, and the toxicity administered p.o. for mice is 660 mg/kg.
De farmasøytiske preparater av fremgangsmåteforbindelsene kan fremstilles i form for oral, parenteral eller lokale admini-strasjons veier . Enhetsdoseformer av tabletter, kapsler eller dragéer, oppløsninger for injeksjon, salver, talcum og sprayer, etc., kan fremstilles. De farmasøytiske preparater kan inneholde uorganiske eller organiske faste eller flytende bærere, som vann, polyethylenglycol, talcum, stivelse, calciumcarbonat, magnesium-stearat , kakaosmør, vaselin, etc. The pharmaceutical preparations of the process compounds can be prepared in the form of oral, parenteral or local routes of administration. Unit dosage forms of tablets, capsules or dragees, solutions for injection, ointments, talcum and sprays, etc., can be prepared. The pharmaceutical preparations may contain inorganic or organic solid or liquid carriers, such as water, polyethylene glycol, talc, starch, calcium carbonate, magnesium stearate, cocoa butter, vaseline, etc.
De vanlige remedier kan også tilsettes som stabilisatorer, desintegreringsmidler, etc. Preparatene fremstilles på i og for seg kjent vis. The usual remedies can also be added as stabilizers, disintegrants, etc. The preparations are prepared in a manner known per se.
Videre detaljer ved foreliggende oppfinnelse er illustrert av de følgende eksempler. Further details of the present invention are illustrated by the following examples.
Fremstilling av utgangsmateriale Production of starting material
28,7 g (0,1 mol) 6,7-dimethoxy-l,2, 3,4-tet rahydro-1 - isokinolin-eddiksyre oppløses i 50 ml vandig oppløsning av 49natriumhydroxyd. Oppløsningen avkjøles til fra -10° til -15 C, 28.7 g (0.1 mol) of 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid are dissolved in 50 ml of an aqueous solution of sodium hydroxide. The solution is cooled to from -10° to -15 C,
og 17 g (0,1 mol) benzyloxycarbonylklorid tildryppes til oppløsningen under avkjøling i løpet av 30 minutter. Den avkjølte reaksjonsbland-ing omrøres i ytterligere 3 timer, hvorefter den surgjøres med 40 ml 20%-ig saltsyre. De utfelte krystaller frafiltreres , vaskes med vann, tørres og omkrystalliseres. Man får 32,592-benzyloxy-carbony1-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isokinolin-eddiksyre.Smp.: 153 - 154°C. and 17 g (0.1 mol) of benzyloxycarbonyl chloride are added dropwise to the solution while cooling over the course of 30 minutes. The cooled reaction mixture is stirred for a further 3 hours, after which it is acidified with 40 ml of 20% hydrochloric acid. The precipitated crystals are filtered off, washed with water, dried and recrystallized. 32,592-benzyloxy-carbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid is obtained. Mp.: 153 - 154°C.
Analyse for formelen c2i<H>26<N>06Analysis for the formula c2i<H>26<N>06
Eksempel 1 Example 1
0,02 mol 2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetra-hydro-l-isokinolin-eddiksyre oppløses i 80 ml vannfri tetrahydrofuran, oppløsningen avkjøles til fra -10 til -15°C, og samtidig tildryppes 0,02 mol triethylamin og 0,02 mol isobutyloxycarbonylklorid i 5 ml tetrahydrofuran i løpet av 5 minutter til oppløsningen under omrøring. Efter omrøring i ytterligere 5 minutter tildryppes 0,02 mol av det tilsvarende amin til reaksjonsblandingen i 20 ml tetrahydrofuran, blandingen omrøres i 5 timer og hensettes over natten. Det utfelte triethylammoniumklorid f ra - filtreres og vaskes med tetrahydrofuran. Tetrahydrofuranoppløs-ningene inndampes. Residuet oppløses i 70 ml ethylacetat og vaskes med 2,6 ml vann og 1% natriumhydroxydoppløsning, og igjen med vann til nøytralitet. Ethylacetatet tørres over natriumsulfat og inndampes i vakuum. Residuet krystalliseres. Data for de erholdte forbindelser er angitt i tabell I. 0.02 mol of 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetra-hydro-1-isoquinoline-acetic acid is dissolved in 80 ml of anhydrous tetrahydrofuran, the solution is cooled to from -10 to -15°C, and at the same time 0.02 mol of triethylamine and 0.02 mol of isobutyloxycarbonyl chloride in 5 ml of tetrahydrofuran are added dropwise over the course of 5 minutes to the solution while stirring. After stirring for a further 5 minutes, 0.02 mol of the corresponding amine is added dropwise to the reaction mixture in 20 ml of tetrahydrofuran, the mixture is stirred for 5 hours and allowed to stand overnight. The precipitated triethylammonium chloride is filtered off and washed with tetrahydrofuran. The tetrahydrofuran solutions are evaporated. The residue is dissolved in 70 ml of ethyl acetate and washed with 2.6 ml of water and 1% sodium hydroxide solution, and again with water to neutrality. The ethyl acetate is dried over sodium sulphate and evaporated in vacuo. The residue is crystallized. Data for the compounds obtained are given in Table I.
Eksempel 2 Example 2
7,7 g (0,02 mol) 2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetrahydro-l-isokinolin-eddiksyre oppløses i 30 ml kloroform, og oppløsningen oppvarmes med 2,839(0,024 mol) thionylklorid under tilbakeløpskokning i 1 time. Reaksjonsblandingen inndampes så i vakuum, og det gjenværende syreklorid oppløses i 10 ml benzen. 7.7 g (0.02 mol) of 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid are dissolved in 30 ml of chloroform, and the solution is heated with 2.839 (0.024 mol) thionyl chloride under reflux for 1 hour. The reaction mixture is then evaporated in vacuo, and the remaining acid chloride is dissolved in 10 ml of benzene.
2,9 g (0,02 mol) 2-amino-kinoxalin oppløses i 10 ml benzen 2.9 g (0.02 mol) of 2-amino-quinoxaline is dissolved in 10 ml of benzene
og tildryppes til blandingen ved 0°C samtidig med oppløsningen av 2-benzyloxycarbonyl-6,7-dimethoxy-1-isokinolyl-acetylklorid fremstilt som beskrevet ovenfor sammen med 15 ml 2 N natriumhydroxyd. Efter at tilsetningen er avsluttet, tillates blandingen å oppvarmes og omrøres ved værelsetemperatur i 3 timer. Efter fraskillelse vaskes benzenskiktet med 2 N natriumhydroxyd og vann. Benzenoppløsningen tørres og inndampes. Man får 9,4 g 2-(2-benzyloxyca rbony1)-6,7-dimethoxy-1 ,2 , 3 ,4~t et rahydro-l-i sokinolyl-acetamido) -kinoxalin. Smp.: 166- - l67°C (fra ethanol og ether). and is added dropwise to the mixture at 0°C simultaneously with the solution of 2-benzyloxycarbonyl-6,7-dimethoxy-1-isoquinolyl-acetyl chloride prepared as described above together with 15 ml of 2 N sodium hydroxide. After the addition is complete, the mixture is allowed to warm and stir at room temperature for 3 hours. After separation, the benzene layer is washed with 2 N sodium hydroxide and water. The benzene solution is dried and evaporated. 9.4 g of 2-(2-benzyloxycarbonyl)-6,7-dimethoxy-1,2,3,4~t rahydro-1-isoquinolyl-acetamido)-quinoxaline are obtained. Mp.: 166- - 167°C (from ethanol and ether).
Eksempel 3 Example 3
10,12 g (0,02 mol) p-nitrofenyl-(2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isokinolin)-acetat og 2,14910.12 g (0.02 mol) p-nitrophenyl-(2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline)-acetate and 2.149
(0,02 mol) p-toluidin oppvarmes i 50 ml toluen under tilbakeløp i (0.02 mol) p-toluidine is heated in 50 ml of toluene under reflux i
3 timer. Reaksjonsblandingen avkjøles og vaskes med 1 N natriumhydroxyd og med vann. Toluenoppløsningen tørres over vannfritt natriumsulfat og inndampes. Man får 9,2 g N-tolyl-(2-benzyloxycarbonyl-6,7-dimethoxy-1,2 ,3,4-tet rahydro-1-isokinolyl)-acet amid. Smp. 167 - 169°C (ethanol). 3 hours. The reaction mixture is cooled and washed with 1 N sodium hydroxide and with water. The toluene solution is dried over anhydrous sodium sulfate and evaporated. 9.2 g of N-tolyl-(2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolyl)-acetamide are obtained. Temp. 167 - 169°C (ethanol).
Eksempel 4 Example 4
7,7 g (0,02 mol) 2-benzyloxycarbony1-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isokinolin-eddiksyre og 1,86 g (O,02 mol) anilin opp-løses i 80 ml tetrahydrofuran, og ved 0°C tildryppes 4,52 g (0,022 mol) dicyclohexyl-carbodiimid oppløst i 20 ml tetrahydrofuran under omrøring. Denne blanding omrøres ved 0°C i 1 time og ved værelsetemperatur i 2 timer. Det utfelte dicyclohexylurea frafiltreres, vaskes med tetrahydrofuran, og filtratet inndampes. 7.7 g (0.02 mol) of 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid and 1.86 g (0.02 mol) of aniline are dissolved in 80 ml of tetrahydrofuran, and at 0°C 4.52 g (0.022 mol) of dicyclohexylcarbodiimide dissolved in 20 ml of tetrahydrofuran are added dropwise while stirring. This mixture is stirred at 0°C for 1 hour and at room temperature for 2 hours. The precipitated dicyclohexylurea is filtered off, washed with tetrahydrofuran, and the filtrate is evaporated.
Man får 9,2 g 2-benzyloxycarbony1-6,7-dimethoxy-1,2,3,4-tetrahydro-l-isokinolyl-acetanilid. Smp.: 104 - lo6°C (benzen:et her) . 9.2 g of 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolyl-acetanilide are obtained. Mp.: 104 - lo6°C (benzene:et here) .
Eksempel 5 Example 5
7,7 g (0,02 mol) 2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetrahydro-l-isokinolin-eddiksyre og 2,9 g (0,02 mol) 2-amino-kinoxalin blandes sammen, og blandingen oppvarmes ved 170 - 180°C 7.7 g (0.02 mol) of 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetic acid and 2.9 g (0.02 mol) of 2-amino- quinoxaline is mixed together, and the mixture is heated at 170 - 180°C
i 3 timer under en svak nitrogenstrøm. Ved avkjøling fåes 8,2 g 2-(2-benzyloxycarbony1-6,7-dimethox<y->l,2,3,4-tetrah<y>dro-1 - isokinolyl-acetamido)-kinoxalin med smp. 165 - l66°C (ethanol:ether for 3 hours under a gentle stream of nitrogen. Upon cooling, 8.2 g of 2-(2-benzyloxycarbonyl-6,7-dimethox<y->1,2,3,4-tetrahydro-1-isoquinolyl-acetamido)-quinoxaline are obtained with m.p. 165 - 166°C (ethanol:ether
Eksempel 6 Example 6
0,02 mol av et av de i tabell I angitte substituerte 2-benzyloxycarbonyl-6,7-dimethoxy-l,2,3,4-tetrahydro-l-isokinolin-acetamider oppløses i en oppløsning av 4 - 5 ekvivalenter 30%-ig hydrogenbromidoppløsning i iseddik. Efter 30 til 50 minutter felles krystaller fra oppløsningen, og oppløsningen blir fast. Efter tilsetning av ether vil felningen av krystaller være fullstendig, og det faste stoff frafiltreres og vaskes med ether. Efter tørring følger omkrystallisasjon. Data for de erholdte produkter er samlet i tabell II. 0.02 mol of one of the substituted 2-benzyloxycarbonyl-6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline-acetamides listed in Table I is dissolved in a solution of 4 - 5 equivalents of 30% ig hydrogen bromide solution in glacial acetic acid. After 30 to 50 minutes, crystals separate from the solution, and the solution becomes solid. After adding ether, the precipitation of crystals will be complete, and the solid substance is filtered off and washed with ether. After drying, recrystallization follows. Data for the products obtained are collected in Table II.
Claims (3)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU76CI1711A HU174697B (en) | 1976-12-30 | 1976-12-30 | Process for producing new 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolin-acetamide derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
NO774500L NO774500L (en) | 1978-07-03 |
NO148108B true NO148108B (en) | 1983-05-02 |
NO148108C NO148108C (en) | 1983-08-10 |
Family
ID=10994635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO774500A NO148108C (en) | 1976-12-30 | 1977-12-29 | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ISOQINOLINE ACETAMIDE DERIVATIVES |
Country Status (18)
Country | Link |
---|---|
JP (1) | JPS5398973A (en) |
BE (1) | BE862444A (en) |
BG (1) | BG29871A3 (en) |
CS (1) | CS208741B2 (en) |
DD (1) | DD139126A5 (en) |
DK (1) | DK583477A (en) |
FI (1) | FI60561C (en) |
FR (1) | FR2376139A1 (en) |
GB (1) | GB1593410A (en) |
GR (1) | GR66084B (en) |
HU (1) | HU174697B (en) |
IL (1) | IL53700A (en) |
NL (1) | NL7714583A (en) |
NO (1) | NO148108C (en) |
PL (1) | PL114677B1 (en) |
PT (1) | PT67473B (en) |
SE (1) | SE7714928L (en) |
SU (1) | SU691087A3 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5587771A (en) * | 1978-12-27 | 1980-07-02 | Teikoku Hormone Mfg Co Ltd | 1-phenylisoquinoline derivative |
DE3827727A1 (en) * | 1988-08-16 | 1990-02-22 | Boehringer Ingelheim Kg | ANALYZED TETRAHYDROPYRIDINE IGNESE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE OF SUCH CONNECTIONS FOR CARDIRO PROTECTION |
-
1976
- 1976-12-30 HU HU76CI1711A patent/HU174697B/en unknown
-
1977
- 1977-12-27 BG BG038228A patent/BG29871A3/en unknown
- 1977-12-27 SU SU772557602A patent/SU691087A3/en active
- 1977-12-27 IL IL53700A patent/IL53700A/en unknown
- 1977-12-28 JP JP15750677A patent/JPS5398973A/en active Pending
- 1977-12-28 DD DD77202985A patent/DD139126A5/en unknown
- 1977-12-28 CS CS778938A patent/CS208741B2/en unknown
- 1977-12-28 GR GR55057A patent/GR66084B/el unknown
- 1977-12-28 FI FI773951A patent/FI60561C/en not_active IP Right Cessation
- 1977-12-28 FR FR7739477A patent/FR2376139A1/en not_active Withdrawn
- 1977-12-29 PT PT67473A patent/PT67473B/en unknown
- 1977-12-29 DK DK583477A patent/DK583477A/en not_active Application Discontinuation
- 1977-12-29 NO NO774500A patent/NO148108C/en unknown
- 1977-12-29 GB GB54179/77A patent/GB1593410A/en not_active Expired
- 1977-12-29 BE BE183942A patent/BE862444A/en unknown
- 1977-12-29 SE SE7714928A patent/SE7714928L/en not_active Application Discontinuation
- 1977-12-30 PL PL1977203486A patent/PL114677B1/en unknown
- 1977-12-30 NL NL7714583A patent/NL7714583A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
SE7714928L (en) | 1978-07-01 |
PT67473A (en) | 1978-01-01 |
IL53700A0 (en) | 1978-03-10 |
FI60561C (en) | 1982-02-10 |
FI773951A (en) | 1978-07-01 |
FI60561B (en) | 1981-10-30 |
GR66084B (en) | 1981-01-15 |
PL114677B1 (en) | 1981-02-28 |
HU174697B (en) | 1980-03-28 |
GB1593410A (en) | 1981-07-15 |
BE862444A (en) | 1978-04-14 |
NL7714583A (en) | 1978-07-04 |
FR2376139A1 (en) | 1978-07-28 |
NO774500L (en) | 1978-07-03 |
IL53700A (en) | 1981-05-20 |
NO148108C (en) | 1983-08-10 |
SU691087A3 (en) | 1979-10-05 |
PT67473B (en) | 1979-05-28 |
BG29871A3 (en) | 1981-02-16 |
DD139126A5 (en) | 1979-12-12 |
JPS5398973A (en) | 1978-08-29 |
DK583477A (en) | 1978-07-01 |
PL203486A1 (en) | 1979-11-19 |
CS208741B2 (en) | 1981-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2760903B2 (en) | Heterocyclic substituted acylaminothiazole | |
JPH01503233A (en) | pharmaceutical active compound | |
JPS604187B2 (en) | Method for producing 4-aminoquinoline derivative | |
US4460771A (en) | Antiphlogistic and anticoagulant condensed pyrimidine derivatives | |
US4404214A (en) | 2-Pyridinecarboxamide derivatives compositions containing same and method of using same | |
FI86173B (en) | FOERFARANDE FOER FRAMSTAELLNING AV FARMAKOLOGISKT VAERDEFULLA SULFONAMIDOETYLFOERENINGAR. | |
JPH04243856A (en) | Substituted phenylacetylene, medicine containing same and process for producing said compund and said medicine | |
NO148108B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ISOQINOLINE ACETAMIDE DERIVATIVES | |
US3726880A (en) | Organic amides and methods for their production | |
DK149625B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF N-SUBSTITUTED (8-HALOGEN OR TRIFLUORMETHYL-4-QUINOLYLAMINO) -BENZAMIDES OR A PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT | |
JPH0692915A (en) | 1,2-diaminocyclobutene-3,4-dione derivative and its use | |
US3647802A (en) | 2-amino-4-aryl-3 4-dihydroquinolines | |
US4568690A (en) | 1-Methyl-5-p-methylbenzoylpyrrole-2-acetamidoacetanilides with antiinflammatory, analgesic, antipyretic and anti-platelet aggregant activity | |
US4532249A (en) | Derivatives of p-acylaminophenol having a therapeutic action, and compositions having a therapeutic action containing said derivatives as pharmacologically active ingredients | |
ES2248230T3 (en) | PIPERAZINILCARBONIL-QUINOLINAS AND ISOQUINOLINAS. | |
CA1100971A (en) | 6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinoline- acetamide derivatives and a process for the preparation thereof and pharmaceutical compositions containing same | |
US5179089A (en) | Isoquinoline compounds, compositions and use | |
US4755523A (en) | Abietamide derivatives | |
US3432491A (en) | Benzene sulfonyl semicarbazides | |
NO312896B1 (en) | New 4- (1-piperazinyl) benzoic acid derivatives, processes for their preparation, and pharmaceutical compositions comprising them | |
US3491113A (en) | Sulphonyl urea derivatives | |
US4643996A (en) | 5-phenyl-2-furoic acid hydrazides | |
JPS63233972A (en) | Novel indole carboxamide derivatives and salts, manufacture and intermediates, use for medicines and composition | |
JPS63130570A (en) | 3,5-di-tert-butyl-4-hydroxycinnamic acid amide derivative | |
US4010161A (en) | Piperazinoethyl-N-(2,3-dimethyl-5-oxo-1-phenyl-3Δ-pyrazolin-4-yl)carbamates |